|Bid||9.72 x 200|
|Ask||9.74 x 200|
|Day's Range||9.52 - 9.84|
|52 Week Range||5.42 - 25.95|
|PE Ratio (TTM)||-3.75|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.14|
The Street reacted to Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE )’s positive Fragile X trial results with marked ambivalence. Investors propelled the stock 76 percent higher even as biotech and behavioral ...
Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
NEW YORK, NY / ACCESSWIRE / September 29, 2017 / Zynerba scored a big win yesterday after announcing positive results from its trial of ZYN002, a cannabidiol gel that is aimed to reduce symptoms of fragile ...
On Thursday, shares of clinical-stage specialty pharmaceutical company Zynerba Pharmaceuticals (ZYNE) are soaring, up nearly 54% in afternoon trading after it announced positive results in a mid-stage study of its cannabis-derived gel treatment.
Zynerba Pharmaceuticals shares saw a huge gain early on Thursday after the firm announced positive results from its mid-stage cannabinoid trial.
ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements. Zynerba to host conference call and webcast today, September 28 at 8:30 am ET. DEVON, Pa., Sept. 28, 2017-- Zynerba ...
While most pot stocks have at least doubled in value over the past 12 months, these two are down nearly 40%!
DEVON, Pa., Sept. 06, 2017-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced ...
The month of August has been hard one for cannabis drug stocks. After Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) reported a pair of disappointing trial results in its Phase 2 STAR 1 and STOP trials, respectively, ...
This clinical-stage cannabinoid-based drug developer has a long way to go to prove its worth to investors.
Zynerba Pharmaceuticals saw its shares sink to a 52-week low after the firm announced results from its midstage trial evaluating cannabidiol gel for the treatment of knee pain due to osteoarthritis.
NEW YORK, NY / ACCESSWIRE / August 14, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
DEVON, Pa., Aug. 14, 2017-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced ...
This week, focus was on earnings announcements from companies like Mylan (MYL), Perrigo and Endo.
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.